Technical Analysis for SRPT - Sarepta Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Shooting Star Candlestick | Bearish | 6.09% | |
| Oversold Stochastic | Weakness | 6.09% | |
| Slingshot Bearish | Bearish Swing Setup | 6.23% | |
| Pocket Pivot | Bullish Swing Setup | 6.23% | |
| Lower Bollinger Band Walk | Weakness | 6.23% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 11 hours ago |
| Rose Above 20 DMA | about 13 hours ago |
| Up 2 ATRs | about 13 hours ago |
| 20 DMA Resistance | about 13 hours ago |
| Up 5% | about 13 hours ago |
Get a Trading Sidekick!
- Earnings date: 04/30/2024
Sarepta Therapeutics, Inc. Description
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Clinical Development Infectious Diseases Rare Diseases Clinical Research Influenza Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Therapeutic Gene Modulation Antisense RNA
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 159.89 |
| 52 Week Low | 55.25 |
| Average Volume | 821,364 |
| 200-Day Moving Average | 111.44 |
| 50-Day Moving Average | 125.86 |
| 20-Day Moving Average | 123.24 |
| 10-Day Moving Average | 119.13 |
| Average True Range | 3.72 |
| RSI (14) | 53.92 |
| ADX | 21.97 |
| +DI | 21.24 |
| -DI | 18.74 |
| Chandelier Exit (Long, 3 ATRs) | 120.01 |
| Chandelier Exit (Short, 3 ATRs) | 125.52 |
| Upper Bollinger Bands | 132.84 |
| Lower Bollinger Band | 113.65 |
| Percent B (%b) | 0.55 |
| BandWidth | 15.57 |
| MACD Line | -1.97 |
| MACD Signal Line | -1.66 |
| MACD Histogram | -0.3146 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 136.13 | ||||
| Resistance 3 (R3) | 135.10 | 130.12 | 134.15 | ||
| Resistance 2 (R2) | 130.12 | 127.09 | 130.63 | 133.49 | |
| Resistance 1 (R1) | 127.18 | 125.22 | 128.65 | 128.21 | 132.83 |
| Pivot Point | 122.20 | 122.20 | 122.93 | 122.71 | 122.20 |
| Support 1 (S1) | 119.26 | 119.17 | 120.73 | 120.29 | 115.67 |
| Support 2 (S2) | 114.28 | 117.30 | 114.79 | 115.01 | |
| Support 3 (S3) | 111.34 | 114.28 | 114.35 | ||
| Support 4 (S4) | 112.37 |
